Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
iRhythm Technologies, Inc.
Optimal duration to monitor patients for identifying nsVT remains unclear. The investigators aim to determine the prevalence and burden of nsVT with longer term monitoring with the iRhythm Zio XT device over a 2-week period vs. 48 hours; and whether, this greater burden of nsVT compared to conventional shorter monitoring potentially identifies a subset of HCM patients who may be at higher risk of sudden cardiac death.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject must be 18 to 65 years of age at time of informed consent and must not be a member of a vulnerable population.
Subject has been diagnosed with hypertrophic cardiomyopathy, as defined by a maximal LV wall thickness of ≥15 mm anywhere in LV wall, in absence of another cause that could be responsible for the LV hypertrophy.
Subject eligible to receive the Zio XT device per the current approved indications for use.
You may not be if
Subject with pacemaker
Known skin allergies or reaction to adhesives
The investigator deems a condition that could limit a subject's ability or unwillingness to participate in the study, comply with study required monitoring and/or follow-up visits.
